Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease.
Complement defense 59 (CD59) is a cell surface glycophosphoinositol (GPI)-anchored protein that prevents complement membrane attack complex (MAC) assembly. Here, we present evidence from ELISA assays that CD59 protein levels are significantly decreased in the frontal cortex and hippocampus of Alzheimer's disease (AD) compared with nondemented elderly (ND) patients, whereas complement component 9, a final component to form MAC, is significantly increased. To further confirm the CD59 deficit, PI-specific phospholipase C (PIPLC) was used to cleave the CD59 GPI anchor at the cell surface in intact slices from AD and ND cortex. CD59 released by PIPLC cleavage was significantly reduced in AD compared with ND samples. By the use of a ribonuclease protection technique, amyloid beta-peptide was found to downregulate CD59 expression at the mRNA level, suggesting a partial explanation of CD59 deficits in the AD brain. To evaluate the pathophysiological significance of CD59 alterations in neurons, we exposed cultured NT2 cells, which normally underexpress CD59, and NT2 cells transfected to overexpress CD59 to homologous human serum. Lactic acid dehydrogenase assays revealed significant complement-induced cell lysis in CD59-underexpressing NT2 cells and significant protection from such lysis in CD59-overexpressing NT2 cells. Moreover, cells expressing normal levels of CD59 showed no evidence of MAC assembly or damage after exposure to homologous serum, whereas pretreatment of these cells with a CD59-neutralizing antibody resulted in MAC assembly at the cell surface and morphological damage. Taken together, these data suggest that CD59 deficits may play a role in the neuritic losses characteristic of AD.
Yang
L B
LB
L. J. Roberts Center for Alzheimer's Research, Sun Health Research Institute, Sun City, Arizona 85351, USA.
Li
R
R
Meri
S
S
Rogers
J
J
Shen
Y
Y
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000276:immunology / Q000378:metabolism* / Q000473:pathology*; D016229:Amyloid beta-Peptides / Q000494:pharmacology; D018957:CD59 Antigens / Q000235:genetics / Q000378:metabolism*; D002454:Cell Differentiation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003186:Complement C9 / Q000235:genetics / Q000378:metabolism; D003165:Complement System Proteins / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005625:Frontal Lobe / Q000378:metabolism / Q000473:pathology; D015870:Gene Expression / Q000187:drug effects; D017261:Glycosylphosphatidylinositols / Q000378:metabolism; D006624:Hippocampus / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D010446:Peptide Fragments / Q000494:pharmacology; D043265:Phosphatidylinositol Diacylglycerol-Lyase; D010751:Phosphopyruvate Hydratase / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D012260:Ribonucleases / Q000172:deficiency / Q000378:metabolism; D016708:Synaptophysin / Q000378:metabolism; D014162:Transfection; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors / Q000378:metabolism
D016229:Amyloid beta-Peptides; D018957:CD59 Antigens; D003186:Complement C9; D017261:Glycosylphosphatidylinositols; D010446:Peptide Fragments; D012333:RNA, Messenger; D016708:Synaptophysin; C075222:amyloid beta-protein (1-42); D003165:Complement System Proteins; D012260:Ribonucleases; D010738:Type C Phospholipases; D010751:Phosphopyruvate Hydratase; D043265:Phosphatidylinositol Diacylglycerol-Lyase